Xeris Biopharma Holdings XERS Insider Ownership

Updated Nov 5, 2026

Over the trailing 12 months, XERS insiders sold $5.81 million worth of shares (755.88K shares) in open-market trades, with no open-market purchases.

• A count shows 9 insiders selling XERS stock on the open market over the past 12 months and none buying.
• Beth Hecht (Officer) was XERS's largest open-market seller in the past 12 months, with $1.72 million of sales (225K shares); the latest was on November 2, 2026.
• In transactions other than open-market trades, Xeris Biopharma Holdings insiders received 1Mn shares in stock awards, acquired 279.2K shares through option exercises and conversions and gave up 902.2K shares to cover taxes or exercise prices over the past 12 months.
• Business Quant data puts insider holdings in XERS at 9.4Mn shares across insiders' latest Form 4 filings, down 4.72% from 9.87Mn shares at the end of Q2 2026.
• Direct holdings account for 9.39Mn shares (99.82%) of XERS's insider total, and indirect holdings through trusts, partnerships and family members for 17.18K shares (0.18%).
• Per Business Quant, 15 insiders of XERS hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Xeris Biopharma Holdings' three biggest insider holders are John Patrick Shannon Jr. (Director and officer, 2.9Mn shares), Kevin McCulloch (Officer, 1.58Mn shares) and Steven Pieper (Officer, 1.35Mn shares), based on their latest Form 4 filings.
• John Patrick Shannon Jr. holds 30.83% of the combined insider position in Xeris Biopharma Holdings.
• Institutions owned 62.19% of XERS shares as of Q2 2026; insiders' latest Form 4 filings account for about 5.42%, leaving roughly 32.39% with other investors, including the public.
• Over the trailing 12 months, 13 insiders reported transactions in XERS stock across 47 Form 4 filings.
• Insider figures for XERS include Form 4 filings through November 4, 2026.